Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
CEO Stéphane Bancel framed the changes as essential to scaling the business
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
